Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

'Trial Meets Primary and Key Secondary Endpoints'

NEW YORK, March 10 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial in patients with Sleep Maintenance Insomnia (SMI). In this study, ITI-007 significantly and dose-dependently increased slow wave sleep and decreased the duration of wake after sleep onset as measured by polysomnography (PSG), meeting the prespecified primary and key secondary endpoints of the trial. ITI-007 also increased total sleep time and sleep efficiency. PSG improvements such as increased total sleep time and slow wave sleep are associated with reports of improved sleep quality. Improvement in these sleep parameters is driven by the unique pharmacology of ITI-007 that can act simultaneously as a 5HT2A receptor antagonist, dopamine receptor phosphoprotein modulator (DPPM), and inhibitor of serotonin reuptake. These additional actions clearly differentiate ITI-007 from other sleep modulating drugs. The present Phase II data suggest the beneficial effects on sleep are a result of ITI-007's distinctive neuropharmacological mechanisms beyond simple 5HT2A receptor antagonism. As such, ITI-007 represents a novel approach for the treatment of insomnia characterized by difficulty in staying asleep, as well as for the treatment of insomnia related to psychiatric and neurologic disorders. These clinical results will be presented at a major scientific meeting in June.

"We are excited to have demonstrated ITI-007's ability to produce such robust improvements on sleep quality," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies. "We believe that the positive effects on sleep in this study are a result of ITI-007's unique pharmacological profile that clearly differentiate it from currently available sleep inducing or sleep maintaining drugs. These data set the stage for further investigation of ITI-007's ability to improve slee
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... August 29, 2014 According to a new ... the global orthobiologics market was valued at USD 3,754.6 million ... USD 5,519.9million in 2019at a CAGR of 5.9% from 2013 ... years and above is afflicted by bone and joint disorders, ... year 2020. This has and will continue to increase the ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... YORK, Aug. 31, 2011 Hadasit Bio-Holdings, Ltd. - ... biotech companies, all based on intellectual property developed and ... center, announced today that its CEO, Mr. Ophir Shahaf, ... Investment Conference in New York City on Tuesday, September ...
... DIEGO, Aug. 31, 2011 BioMed Realty Trust, Inc. ... that holders of the 4.50% Exchangeable Senior Notes due ... partnership, BioMed Realty, L.P. (the "Operating Partnership"), which are ... right to surrender their Notes for purchase by the ...
... Aug. 30, 2011 Savvier consumers and competition from ... entry or during brand maturity, more elusive.  At the ... of cost-efficient Public Relations to support pharmaceutical brand growth. ... Relations to support their brands, recent field research from ...
Cached Biology Technology:Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011 2BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026 2BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026 3BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026 4BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026 5Using Public Relations to Launch, Grow, and Extend Pharmaceutical and Biotech Brands 2
(Date:8/29/2014)... available in German . ... the natural nitrogen cycle on Earth and in biological ... thought to depend on nitrite as their source of ... Daims, a microbiologist at the University of Vienna, has ... an alternative source of energy. The oxidation of hydrogen ...
(Date:8/29/2014)... . The ... oldest form of communication. Acting as messenger molecules, pheromones ... attraction between males and females. Fish rely on pheromones ... in males and females. Scientists at the Marine Science ... Portugal, and at the Max Planck Institute for Chemical ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Ready for mating at the right time 2Ready for mating at the right time 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... make the spread of deadly strains of avian flu ... Edinburgh and Warwick have found. The research shows that ... birds, the disease is likely to spread unless almost ... published in Nature journal, is the first to quantify ...
... transplants of embryonic stem cell-derived motor neurons in ... partially restore function in paralyzed animals. The study ... treating such disorders as spinal cord injury, transverse ... atrophy. The study was funded in part by ...
... cultured in the laboratory during in vitro fertilisation ... with certain developmental syndromes and other abnormalities in ... , Researchers told the 22nd annual conference of ... today (Monday) that preliminary work investigating genetic imprinting ...
Cached Biology News:Bird flu study highlights need to vaccinate flocks effectively 2Neurons grown from embryonic stem cells restore function in paralyzed rats 2Neurons grown from embryonic stem cells restore function in paralyzed rats 3Neurons grown from embryonic stem cells restore function in paralyzed rats 4How IVF could be causing genetic errors in embryos 2How IVF could be causing genetic errors in embryos 3